The house is quiet, rain is steadily pouring outside, and I’m on my third cup of coffee, but the words aren’t coming easily this month. The truth is, I have a confession to make, and like any other confession, it’s hard to begin.

But, here goes: I haven’t been a very good caregiver lately.

It took me awhile to come to this realization. You see, I strive to be a great caregiver to my husband, Daniel. We’ve been in our …

Welcome, myeloma world, to the first "Acronym Edition" of Myeloma Morning.

Every major news item in today's report is closely linked with one or more acronyms. Once we realized this – and once we also realized that this will probably happen again in the future – we realized we had to mark the occasion in some special way.

Hence: Acronym Edition.

We have three brief research summaries at the beginning of today's report, followed by an extended Q&A.

The first …

Hello, myeloma world. We hope your week has started well.

We have one main item on the agenda for today's edition of Myeloma Morning.

In particular, we want to discuss a topic that is the focus of the only article in our daily list of new myeloma-related research publications, included at the end of this report.

The topic of that article is monoclonal gammopathy of renal significance (MGRS).

Now, most Beacon readers probably have heard of monoclonal …

A happy Sunday to you, myeloma world.

We hope you have been having a pleasant weekend. We've been looking over some of the new multiple myeloma research published in the past few days, and there are two studies we thought we would discuss with you in today's Myeloma Morning.

The first is a case report involving a myeloma patient who has been in remission for more than 15 years. This remission, it seems, may be an unexpected …

A happy Saturday to you, myeloma world.

We have some good news to report today. It also is im­por­tant news related to Darzalex (dara­tu­mu­mab).

Some addi­tional clin­i­cal trial results related to Darzalex were made public earlier this week, but they have not received much attention.

The new results show that adding Darzalex to Velcade (bor­tez­o­mib) and dexa­metha­sone sub­stan­tially – some might even say dramatically – extends pro­gres­sion-free survival in re­lapsed multiple myeloma patients.

The new results expand …

The world may not be ready for the 500th column on the joys of dexa­meth­a­sone (Decadron), but today is a dex day for me, so here it goes anyway.

I have a fair bit of experience with the corticosteroid dex, starting with my myeloma diagnosis back in 2006. My initial treatment consisted of thalido­mide (Thalomid) and dex, and I was on the two drugs for about eight months. This combination did well, getting me into complete re­mission before …

Good morning, myeloma world.

Things have settled down here at Myeloma Morning Headquarters compared to how they were 36 hours ago. We once again have 21^st century tech­nology doing what it is supposed to be doing. It's wonderful.

Speaking of wonderful, let's talk some more about the multiple myeloma research to be presented at the upcoming 2016 annual meeting of the American Society of Clinical Oncology (ASCO). We discussed the meeting in the previous edition of Myeloma Morning, noting …